TAS-119

• CAT Number: I044674
• CAS Number: 1453099-83-6
• Molecular Formula: C23H22Cl2FN5O3
• Molecular Weight: 506.36
• Purity: ≥95%
• Synonyms: 1-(2,3-dichlorobenzoyl)-4-[[5-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl]methyl]piperidine-4-carboxylic acid
• InChI: InChI=1S/C23H22Cl2FN5O3/c1-13-11-18(30-29-13)28-20-17(26)6-5-14(27-20)12-23(22(33)34)7-9-31(10-8-23)21(32)15-3-2-4-16(24)19(15)25/h2-6,11H,7-10,12H2,1H3,(H,33,34)(H2,27,28,29,30)
• InChIKey: PLAVWQHGBMTMFR-UHFFFAOYSA-N
• SMILES: CC1=CC(=NN1)NC2=C(C=CC(=N2)CC3(CCN(CC3)C(=O)C4=C(C(=CC=C4)Cl)Cl)C(=O)O)F

TAS-119（Cat No.:I044674）is a selective, oral inhibitor of Aurora A kinase, a critical enzyme involved in mitotic spindle assembly and chromosome segregation during cell division. By targeting Aurora A, TAS-119 disrupts mitosis in rapidly proliferating cancer cells, leading to cell cycle arrest and apoptosis. It has demonstrated antitumor activity in preclinical models, particularly in cancers with Aurora A overexpression or MYC-driven pathways, such as neuroblastoma and certain solid tumors. TAS-119 is under clinical investigation as a targeted therapy, with the goal of offering improved specificity and reduced toxicity compared to earlier mitotic inhibitors.